Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ENDV NASDAQ:FLXN NASDAQ:MTEM NASDAQ:RAPT NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENDVEndonovo Therapeutics$0.00-50.0%$0.00$0.00▼$0.00$120K-1.374.29 million shs4.94 million shsFLXNFlexion Therapeutics$25.76+0.3%$9.20$4.30▼$13.66$1.30B1.531.18 million shs1,378 shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.535.62 million shsN/ARAPTRapt Therapeutics$29.53-1.6%$20.63$5.67▼$42.39$488.37M0.23689,213 shs555,135 shsVNDAVanda Pharmaceuticals$5.50+0.2%$4.90$3.81▼$5.62$324.99M0.74573,210 shs514,904 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENDVEndonovo Therapeutics0.00%0.00%0.00%-50.00%-90.00%FLXNFlexion Therapeutics+0.29%+0.57%+0.47%+2.36%+182.46%MTEMMolecular Templates0.00%0.00%0.00%0.00%-99.99%RAPTRapt Therapeutics0.00%+0.65%+20.78%+121.86%+114.61%VNDAVanda Pharmaceuticals0.00%+4.36%+13.87%+16.03%+17.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENDVEndonovo Therapeutics$0.00-50.0%$0.00$0.00▼$0.00$120K-1.374.29 million shs4.94 million shsFLXNFlexion Therapeutics$25.76+0.3%$9.20$4.30▼$13.66$1.30B1.531.18 million shs1,378 shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.535.62 million shsN/ARAPTRapt Therapeutics$29.53-1.6%$20.63$5.67▼$42.39$488.37M0.23689,213 shs555,135 shsVNDAVanda Pharmaceuticals$5.50+0.2%$4.90$3.81▼$5.62$324.99M0.74573,210 shs514,904 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENDVEndonovo Therapeutics0.00%0.00%0.00%-50.00%-90.00%FLXNFlexion Therapeutics+0.29%+0.57%+0.47%+2.36%+182.46%MTEMMolecular Templates0.00%0.00%0.00%0.00%-99.99%RAPTRapt Therapeutics0.00%+0.65%+20.78%+121.86%+114.61%VNDAVanda Pharmaceuticals0.00%+4.36%+13.87%+16.03%+17.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENDVEndonovo Therapeutics 0.00N/AN/AN/AFLXNFlexion Therapeutics 0.00N/AN/AN/AMTEMMolecular Templates 0.00N/AN/AN/ARAPTRapt Therapeutics 2.67Moderate Buy$33.0011.75% UpsideVNDAVanda Pharmaceuticals 2.67Moderate Buy$16.50200.00% UpsideCurrent Analyst Ratings BreakdownLatest RAPT, VNDA, ENDV, MTEM, and FLXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025RAPTRapt TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025VNDAVanda PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/21/2025RAPTRapt TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$38.00 ➝ $48.0010/21/2025RAPTRapt TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $58.0010/20/2025RAPTRapt TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$13.00 ➝ $55.0010/13/2025RAPTRapt TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight ➝ Overweight$35.0010/13/2025RAPTRapt TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Overweight$35.0010/8/2025RAPTRapt TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VNDAVanda PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RAPTRapt TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VNDAVanda PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENDVEndonovo Therapeutics$10K12.07N/AN/A($0.08) per share0.00FLXNFlexion Therapeutics$85.55M15.15N/AN/A($0.34) per share-75.76MTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00RAPTRapt Therapeutics$1.53M319.23N/AN/A$11.51 per share2.57VNDAVanda Pharmaceuticals$198.77M1.64N/AN/A$9.24 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENDVEndonovo Therapeutics-$2.80MN/A0.00∞N/AN/AN/AN/AN/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AMTEMMolecular Templates-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/ARAPTRapt Therapeutics-$129.87M-$14.17N/AN/AN/AN/A-67.92%-59.59%11/11/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$1.13N/AN/AN/A-32.90%-12.89%-10.47%10/29/2025 (Estimated)Latest RAPT, VNDA, ENDV, MTEM, and FLXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025RAPTRapt Therapeutics-$0.84N/AN/AN/AN/AN/A10/29/2025Q3 2025VNDAVanda Pharmaceuticals-$0.38N/AN/AN/A$58.73 millionN/A8/7/2025Q2 2025RAPTRapt Therapeutics-$0.61-$0.65-$0.04-$0.65N/AN/A7/31/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34-$0.46-$0.12-$0.46$54.77 million$52.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENDVEndonovo TherapeuticsN/AN/AN/AFLXNFlexion TherapeuticsN/A4.384.05MTEMMolecular TemplatesN/A1.561.56RAPTRapt TherapeuticsN/A13.2513.25VNDAVanda PharmaceuticalsN/A3.253.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENDVEndonovo TherapeuticsN/AFLXNFlexion Therapeutics90.01%MTEMMolecular Templates95.47%RAPTRapt Therapeutics99.09%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipENDVEndonovo Therapeutics5.61%FLXNFlexion Therapeutics9.13%MTEMMolecular Templates13.90%RAPTRapt Therapeutics2.36%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENDVEndonovo Therapeutics11.21 billion1.14 billionNot OptionableFLXNFlexion Therapeutics25750.32 million45.73 millionNo DataMTEMMolecular Templates2606.58 million5.67 millionNo DataRAPTRapt Therapeutics8016.54 million16.15 millionOptionableVNDAVanda Pharmaceuticals29059.09 million53.18 millionOptionableRAPT, VNDA, ENDV, MTEM, and FLXN HeadlinesRecent News About These CompaniesWeiss Ratings Reiterates "Sell (D-)" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)October 25 at 8:21 PM | marketbeat.comVanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on WednesdayOctober 24 at 4:22 PM | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?October 24 at 3:56 AM | marketbeat.comVanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025October 22, 2025 | prnewswire.comVanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Crosses Above 200 Day Moving Average - What's Next?October 16, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)October 9, 2025 | marketbeat.comMonumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown ArenaOctober 8, 2025 | prnewswire.comVanda Pharmaceuticals, FDA agree to resolve disputes on Hetlioz and tradipitantOctober 1, 2025 | msn.comVanda Pharmaceuticals Reaches Agreement with FDAOctober 1, 2025 | tipranks.comVanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug AdministrationOctober 1, 2025 | prnewswire.comVanda Pharmaceuticals’ Hetlioz meets primary endpoints in insomnia studySeptember 25, 2025 | msn.comVanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"September 25, 2025 | prnewswire.comVanda: Next Phase Of Fanapt Growth Might Be With Bysanti AdvancementAugust 29, 2025 | seekingalpha.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia ...August 29, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces Participation at September 2025 Investor ConferencesAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals gets FDA orphan drug status for VGT-1849BAugust 28, 2025 | seekingalpha.comVanda Pharmaceuticals stock rises after FDA orphan drug designationAugust 28, 2025 | za.investing.comVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia VeraAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals treatment of polycythemia vera granted orphan designationAugust 27, 2025 | msn.comVanda seeks FDA Commissioner review of Hetlioz generic rulingAugust 22, 2025 | msn.comVanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®August 21, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRAPT, VNDA, ENDV, MTEM, and FLXN Company DescriptionsEndonovo Therapeutics OTCMKTS:ENDV$0.0001 0.00 (-50.00%) As of 10/24/2025 03:32 PM EasternEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Molecular Templates NASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Rapt Therapeutics NASDAQ:RAPT$29.53 -0.47 (-1.57%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$29.05 -0.48 (-1.63%) As of 10/24/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyVanda Pharmaceuticals NASDAQ:VNDA$5.50 +0.01 (+0.18%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.57 +0.07 (+1.27%) As of 10/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
